Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer

SAN DIEGO, July 21, 2017

"Neurocrine is delighted to welcome Julie Cooke as our Chief People Officer to lead our Human Resource function," said David-Alexandre C. Gros, President and Chief Operating Officer of Neurocrine Biosciences. "Julie's deep and broad experience across all aspects of human resources will be tremendously valuable as we grow and continue to expand our capabilities while remaining true to the culture that has underpinned our success."

"Neurocrine is a remarkably patient focused, innovative and culture driven company," said Ms. Cooke. "I am very excited to join the company during this pivotal growth phase."

Julie Cooke comes to Neurocrine from the Sanford Burnham Prebys Medical Research Institute where she served as Senior Vice President for Human Resources and was a member of the executive management team. Previously, Ms. Cooke held multiple positions at the Vice President level at Life Technologies, including being the human resource partner to the Chief Operating Officer, Division Presidents and Global Function Leads. Prior to Life Technologies, she ran human resources and was a member of the executive management team at SGX Pharmaceuticals. Ms. Cooke began her career at PepsiCo, The Pepsi Bottling Group, and Gateway, where she held positions of increasing responsibility in human resources. She holds a Bachelor of Arts in Economics from Colorado College.

About Neurocrine Biosciences

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).  INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD.  The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.